The grant is set to enhance patient outcomes and quality of life for those with inflammatory bowel disease Credit: Peakstock/Shutterstock.

Takeda Canada has co-sponsored the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) PIONEER Grant to boost clinical research efforts.

The company contributed C$500,000 ($356,932) of the C$1m grant, which aims to support high-quality clinical research in the country to enhance patient outcomes and quality of life for those with inflammatory bowel disease (IBD).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This year, Dr Kevan Jacobson and Dr Genelle Lunken from BC Children’s Hospital received the PIONEER Grant for their research on the study of dietary intervention in Crohn’s disease patients.

The study is titled ‘Open Label Multicentre Randomised Dietary Intervention Study in Paediatric Crohn’s Disease Patients Initiating Anti-TNF Therapy (DISPENSE-T).’

At present, CIRC is running nine multi-centre, investigator-initiated trials, including four multi-centred randomised controlled trials, to address critical clinical questions in IBD management.

Takeda Canada general manager Vatro Mateljic said: “At Takeda, we remain deeply committed to advancing scientific research in IBD and are honoured to continue our support through the CIRC PIONEER Grant.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We congratulate Dr Jacobson and Dr Lunken for their innovative project that could significantly impact the lives of children living with IBD.”

The main forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). It causes chronic inflammation of the gastrointestinal (GI) tract.

This condition affects more than 322,000 Canadians, and despite ongoing research, there is still no cure.

CIRC president and McGill University gastroenterologist Dr Talat Bessissow said: “The PIONEER Grant exemplifies our commitment to advancing high-quality scientific research through collaboration. This study holds the potential to yield transformative insights and set new standards in IBD care, thanks to our Canadian investigators.”

In June, Takeda announced positive outcomes from its Phase IIb clinical trial of mezagitamab (TAK-079) for treating primary immune thrombocytopenia (ITP).